Sp 26

Globe Newswire - Dec 18th, 2024
Score 7.8

Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia

Key preclinical milestone for novel, non-opioid extended-release pain therapeutic

Previous Next

Showing 1 to 1 of 1 results